Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NXL
stocks logo

NXL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for Nexalin Technology Inc (NXL.O) is -2.24, compared to its 5-year average forward P/E of -1.88. For a more detailed relative valuation and DCF analysis to assess Nexalin Technology Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.88
Current PE
-2.24
Overvalued PE
0.35
Undervalued PE
-4.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
42.96
Current PS
0.00
Overvalued PS
93.37
Undervalued PS
-7.45
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 117.11% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 117.11% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

NXL News & Events

Events Timeline

(ET)
2025-12-03
08:10:00
Nexalin Completes Key Q-Submission Meeting with FDA
select
2025-11-18 (ET)
2025-11-18
09:38:28
Nexalin Reveals Outcomes for 15 mA Neurostimulation Device
select
2025-11-13 (ET)
2025-11-13
09:16:58
Nexalin Technology names Carmi Masha as its sole distributor in Israel.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-03Newsfilter
Nexalin Completes Q-Submission Meeting with FDA to Advance Alzheimer's Treatment
  • Successful FDA Meeting: Nexalin's completion of the Q-Submission meeting with the FDA marks a significant advancement in its clinical development plan for the Gen-2 SYNC™ neurostimulation console aimed at treating Alzheimer's disease.
  • Exploring New Pathways: The discussion included the potential use of the De Novo classification pathway, reflecting the innovative mechanism of Nexalin's deep frequency-specific neurostimulation technology, laying the groundwork for future regulatory approvals.
  • Clinical Trial Design: Nexalin and the FDA reached alignment on foundational elements of trial design, including patient population and statistical analysis plans, ensuring scientific rigor and efficacy for upcoming pilot and pivotal studies.
  • Safety and Efficacy: The Gen-2 SYNC console has demonstrated a favorable safety profile in international trials, with studies indicating significant improvements in cognitive performance for Alzheimer's patients, supporting the company's U.S. development strategy.
[object Object]
Preview
7.5
11-13Newsfilter
Nexalin Technology Names Carmi Masha Technologies Ltd. as Sole Distributor for Israel

  • Exclusive Distribution Agreement: Nexalin Technology has signed an exclusive distribution agreement with Carmi Masha Technologies to market its Gen-2 Console ("SYNC") neurostimulation device in Israel, following regulatory approval for its use in treating mental health disorders.

  • Focus on Mental Health Treatment: The SYNC device is designed to provide non-invasive, drug-free treatment for conditions such as insomnia, depression, and anxiety, with potential future applications for PTSD, TBI, and dementia.

  • Partnership Goals: The collaboration aims to leverage Carmi Masha's expertise in introducing medical technologies to enhance access to Nexalin's innovative solutions in Israel, aligning with the growing demand for effective mental health treatments.

  • Global Expansion Strategy: This agreement is part of Nexalin's broader strategy to expand its presence in international markets, particularly in the Middle East, while continuing to develop advanced neurostimulation products for mental health issues.

[object Object]
Preview
9.0
11-05Newsfilter
Nexalin Technology's Q-Submission for Gen-2 SYNC Approved by U.S. FDA for Alzheimer's Disease and Dementia Treatment

  • FDA Acceptance: Nexalin Technology's Q-Submission for its Gen-2 Console ("SYNC") system aimed at treating Alzheimer's disease and dementia has been accepted by the FDA, marking a significant step towards initiating U.S. clinical studies.

  • Clinical Trial Discussion: The upcoming regulatory meeting with the FDA will focus on clinical trial design, study endpoints, and the regulatory pathway for evaluating the SYNC system as a non-invasive therapy for cognitive impairments.

  • Positive Internal Data: Recent internal data and published research indicate improvements in cognitive performance and a favorable safety profile for Nexalin's neurostimulator, which utilizes a proprietary waveform technology.

  • Strategic Collaborations: Nexalin is exploring partnerships with leading research institutions to expedite both U.S. and international studies involving its Gen-2 SYNC and next-generation Gen-3 HALO platforms.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Nexalin Technology Inc (NXL) stock price today?

The current price of NXL is 0.963 USD — it has decreased -2.23 % in the last trading day.

arrow icon

What is Nexalin Technology Inc (NXL)'s business?

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.

arrow icon

What is the price predicton of NXL Stock?

Wall Street analysts forecast NXL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NXL is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Nexalin Technology Inc (NXL)'s revenue for the last quarter?

Nexalin Technology Inc revenue for the last quarter amounts to 18.15K USD, decreased -49.63 % YoY.

arrow icon

What is Nexalin Technology Inc (NXL)'s earnings per share (EPS) for the last quarter?

Nexalin Technology Inc. EPS for the last quarter amounts to -0.13 USD, decreased -43.48 % YoY.

arrow icon

What changes have occurred in the market's expectations for Nexalin Technology Inc (NXL)'s fundamentals?

The market is revising No Change the revenue expectations for Nexalin Technology, Inc. (NXL) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 15.18%.
arrow icon

How many employees does Nexalin Technology Inc (NXL). have?

Nexalin Technology Inc (NXL) has 6 emplpoyees as of December 05 2025.

arrow icon

What is Nexalin Technology Inc (NXL) market cap?

Today NXL has the market capitalization of 17.96M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free